140 related articles for article (PubMed ID: 36354085)
21. Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease.
Roberts MM; Juttner CA; To LB; Kimber RJ
Leuk Res; 1988; 12(10):817-21. PubMed ID: 3199841
[TBL] [Abstract][Full Text] [Related]
22. Low L-selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Nuessler V; Schmetzer H
Eur J Haematol; 2003 Nov; 71(5):366-76. PubMed ID: 14667200
[TBL] [Abstract][Full Text] [Related]
23. Proposal for a classification of acute myeloid leukaemia based on plastic-embedded bone marrow biopsy sections.
Islam A
Leuk Res; 1993 May; 17(5):421-7. PubMed ID: 8501969
[TBL] [Abstract][Full Text] [Related]
24. Abnormal morphological and functional nature of bone marrow stromal cells provides preferential support for survival of acute myeloid leukemia cells.
Yehudai-Resheff S; Attias-Turgeman S; Sabbah R; Gabay T; Musallam R; Fridman-Dror A; Zuckerman T
Int J Cancer; 2019 May; 144(9):2279-2289. PubMed ID: 30548585
[TBL] [Abstract][Full Text] [Related]
25. Management of acute myeloid leukaemia--5 years experience at Armed Forces Bone Marrow Transplant Centre, Rawalpindi.
Ullah K; Ahmed P; Raza S; Satti TM; Chaudhry QU; Akhtar F; Kamal MK; Akhtar FM; Khan B
J Pak Med Assoc; 2007 Sep; 57(9):434-9. PubMed ID: 18072636
[TBL] [Abstract][Full Text] [Related]
26. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
27. A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy.
Kim DY; Lee JH; Sym SJ; Yun SC; Lee JH; Kim SD; Choi Y; Lee YS; Kang YA; Jeon M; Seol M; Lee KH; Lee YJ; Lee KH
Ann Hematol; 2011 Nov; 90(11):1283-91. PubMed ID: 21484304
[TBL] [Abstract][Full Text] [Related]
28. Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche.
Boyd AL; Reid JC; Salci KR; Aslostovar L; Benoit YD; Shapovalova Z; Nakanishi M; Porras DP; Almakadi M; Campbell CJV; Jackson MF; Ross CA; Foley R; Leber B; Allan DS; Sabloff M; Xenocostas A; Collins TJ; Bhatia M
Nat Cell Biol; 2017 Nov; 19(11):1336-1347. PubMed ID: 29035359
[TBL] [Abstract][Full Text] [Related]
29. Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia.
Skelding KA; Barry DL; Theron DZ; Lincz LF
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614005
[TBL] [Abstract][Full Text] [Related]
30. Distinct roles of mesenchymal stem and progenitor cells during the development of acute myeloid leukemia in mice.
Xiao P; Sandhow L; Heshmati Y; Kondo M; Bouderlique T; Dolinska M; Johansson AS; Sigvardsson M; Ekblom M; Walfridsson J; Qian H
Blood Adv; 2018 Jun; 2(12):1480-1494. PubMed ID: 29945938
[TBL] [Abstract][Full Text] [Related]
31. Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.
Brune MM; Stüssi G; Lundberg P; Vela V; Heim D; Manz MG; Haralambieva E; Pabst T; Banz Y; Bargetzi M; Grobholz R; Fehr M; Cogliatti S; Ossenkoppele GJ; Löwenberg B; Rudolf CB; Li Q; Passweg J; Mazzuchelli L; Medinger M; Tzankov A;
Ann Hematol; 2021 May; 100(5):1169-1179. PubMed ID: 33704530
[TBL] [Abstract][Full Text] [Related]
32. Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial.
Jädersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzén S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Östling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Höglund M; Henter JI; Herold N
J Intern Med; 2022 Dec; 292(6):925-940. PubMed ID: 35934913
[TBL] [Abstract][Full Text] [Related]
33. IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia.
Kuett A; Rieger C; Perathoner D; Herold T; Wagner M; Sironi S; Sotlar K; Horny HP; Deniffel C; Drolle H; Fiegl M
Sci Rep; 2015 Dec; 5():18411. PubMed ID: 26674118
[TBL] [Abstract][Full Text] [Related]
34. Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells.
Kouzi F; Zibara K; Bourgeais J; Picou F; Gallay N; Brossaud J; Dakik H; Roux B; Hamard S; Le Nail LR; Hleihel R; Foucault A; Ravalet N; Rouleux-Bonnin F; Gouilleux F; Mazurier F; Bene MC; Akl H; Gyan E; Domenech J; El-Sabban M; Herault O
Oncogene; 2020 Feb; 39(6):1198-1212. PubMed ID: 31649334
[TBL] [Abstract][Full Text] [Related]
35. Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy.
Vaxevanis CK; Bauer M; Subbarayan K; Friedrich M; Massa C; Biehl K; Al-Ali HK; Wickenhauser C; Seliger B
Oncoimmunology; 2023; 12(1):2152998. PubMed ID: 36531688
[TBL] [Abstract][Full Text] [Related]
36. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
[TBL] [Abstract][Full Text] [Related]
37. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Karjalainen R; Pemovska T; Popa M; Liu M; Javarappa KK; Majumder MM; Yadav B; Tamborero D; Tang J; Bychkov D; Kontro M; Parsons A; Suvela M; Mayoral Safont M; Porkka K; Aittokallio T; Kallioniemi O; McCormack E; Gjertsen BT; Wennerberg K; Knowles J; Heckman CA
Blood; 2017 Aug; 130(6):789-802. PubMed ID: 28619982
[TBL] [Abstract][Full Text] [Related]
38. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia.
Xia B; Tian C; Guo S; Zhang L; Zhao D; Qu F; Zhao W; Wang Y; Wu X; Da W; Wei S; Zhang Y
Leuk Res; 2015 Jan; 39(1):92-9. PubMed ID: 25443862
[TBL] [Abstract][Full Text] [Related]
39. Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment.
Abdul-Aziz AM; Sun Y; Hellmich C; Marlein CR; Mistry J; Forde E; Piddock RE; Shafat MS; Morfakis A; Mehta T; Di Palma F; Macaulay I; Ingham CJ; Haestier A; Collins A; Campisi J; Bowles KM; Rushworth SA
Blood; 2019 Jan; 133(5):446-456. PubMed ID: 30401703
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of plasmacytosis in the day+14 bone marrow of patients with acute myeloid leukaemia undergoing induction chemotherapy.
Al-Shughair N; Al-Dawsari G; Gyger M; Mohamed G; Roberts G
J Clin Pathol; 2007 May; 60(5):520-3. PubMed ID: 16731597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
